If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Axon Enterprise ( NASDAQ:AXON )
Axon Enterprise AXON has outperformed the market over the past 5 years by 38.75% on an annualized basis producing an average annual return of 52.74%. Currently, Axon Enterprise has a market capitalization of $60.61 billion.
As Layoffs Mount, One Question Is Getting Louder: What Happens To Skyscraper Offices In Cities Like Boston When People Are Replaced By AI?
As artificial intelligence keeps reshaping the workforce, more people are starting to wonder what will happen to all the towering office buildings in downtown areas. With companies pushing for efficiency and reducing headcounts, large office spaces are already sitting half-empty.
CIVIC Is Shaping the Future of Sports--One Fan Experience at a Time
With sports marketing spend to reach $115 billion in 2025 and women's leagues surging into the spotlight, CIVIC is reimagining how brands connect with fans-from stadium roars to race-day cheers
VoIP-Pal Files Antitrust Lawsuit Against Google, Apple, and Samsung
VoIP-Pal files a new antitrust lawsuit against Apple, Google, and Samsung alleging antitrust violations.
Bitcoin Wobbles At $107,000: What Does Technical Analysis Say?
Analyst Benjamin Cowen says Bitcoin may have already peaked, citing a historical moving average signal. DonAlt, on the other hand, remains bullish, pointing to strength across timeframes and solid technical support levels. Historic Summer Setup: 3 'Power Patterns' Triggering in the next 75 Days ...
This Datavault AI Analyst Turns Bullish; Here Are Top 2 Upgrades For Thursday - Core Natural Resources ( NYSE:CNR ) , Coinbase Global ( NASDAQ:COIN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the ...
